Charles Schwab Investment Management Inc Reata Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$79.22 - $105.37 $727,794 - $968,034	9,187 Added 4.44%	216,012 $22 Million
Q1 2023 May 11, 2023	BUY	$30.85 - $93.17 $24,834 - $75,001	805 Added 0.39%	206,825 $18.8 Million
Q4 2022 Feb 13, 2023	BUY	$22.15 - $42.11 $76,661 - $145,742	3,461 Added 1.71%	206,020 $7.83 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $146,526 - $275,463	7,549 Added 3.87%	202,559 $5.09 Million
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $106,511 - $187,719	-5,143 Reduced 2.57%	195,010 $5.93 Million
Q1 2022 May 13, 2022	BUY	$24.12 - $39.6 $157,407 - $258,429	6,526 Added 3.37%	200,153 $6.56 Million
Q4 2021 Feb 11, 2022	BUY	$25.61 - $110.96 $78,443 - $339,870	3,063 Added 1.61%	193,627 $5.11 Million
Q3 2021 Nov 16, 2021	BUY	$100.0 - $143.02 $492,900 - $704,945	4,929 Added 2.66%	190,564 $19.2 Million
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $4.63 Million - $8.95 Million	59,185 Added 46.81%	185,635 $26.3 Million
Q1 2021 May 17, 2021	SELL	$94.25 - $132.81 $406,029 - $572,145	-4,308 Reduced 3.29%	126,450 $12.6 Million
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $1.26 Million - $2.28 Million	12,372 Added 10.45%	130,758 $16.2 Million
Q3 2020 Nov 13, 2020	SELL	$93.53 - $163.34 $1.15 Million - $2.01 Million	-12,285 Reduced 9.4%	118,386 $11.5 Million
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $4.1 Million - $5.73 Million	-32,448 Reduced 19.89%	130,671 $20.4 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $1.61 Million - $3.22 Million	12,978 Added 8.64%	163,119 $23.5 Million
Q4 2019 Feb 07, 2020	BUY	$74.57 - $217.92 $1.26 Million - $3.69 Million	16,913 Added 12.69%	150,141 $30.7 Million
Q3 2019 Nov 08, 2019	BUY	$71.26 - $95.75 $2.27 Million - $3.05 Million	31,902 Added 31.48%	133,228 $10.7 Million
Q2 2019 Aug 09, 2019	BUY	$77.72 - $94.35 $389,843 - $473,259	5,016 Added 5.21%	101,326 $9.56 Million
Q1 2019 May 14, 2019	BUY	$51.9 - $101.79 $255,192 - $500,501	4,917 Added 5.38%	96,310 $8.23 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $76.44 $14,432 - $22,626	-296 Reduced 0.32%	91,393 $5.13 Million
Q3 2018 Nov 13, 2018	BUY	$35.64 - $92.06 $747,976 - $1.93 Million	20,987 Added 29.68%	91,689 $7.5 Million
Q2 2018 Aug 08, 2018	BUY	$19.94 - $40.96 $423,605 - $870,154	21,244 Added 42.95%	70,702 $2.47 Million
Q1 2018 May 07, 2018	BUY	$20.0 - $30.19 $28,080 - $42,386	1,404 Added 2.92%	49,458 $1.02 Million
Q4 2017 Jan 17, 2018	SELL	$22.39 - $33.27 $39,719 - $59,020	-1,774 Reduced 3.56%	48,054 $1.36 Million
Q3 2017 Nov 13, 2017	BUY	$26.29 - $31.88 $1.31 Million - $1.59 Million	49,828	49,828 $1.55 Million

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account